Tourmaline Bio logo

Tourmaline BioNASDAQ: TRML

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

07 May 2021

Next earnings report:

19 March 2025

Last dividends:

N/A

Next dividends:

N/A
$634.91 M
-45%vs. 3y high
70%vs. sector
-vs. 3y high
-vs. sector
-65%vs. 3y high
57%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 70 min ago
$24.76+$1.27(+5.41%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

TRML Latest News

Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
globenewswire.com14 November 2024 Sentiment: POSITIVE

NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it will host a virtual Investor Day on December 10, 2024, beginning at 10 a.m. ET. The event will include presentations from Tourmaline's leadership team and Dr. Marc Bonaca, a cardiologist and vascular medicine specialist serving as Executive Director of CPC Clinical Research and Professor of Medicine and William R.

Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
globenewswire.com07 November 2024 Sentiment: POSITIVE

– On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled Cardiovascular Scientific Advisory Board (CV SAB), comprised of leading academic and industry experts, in October 2024 – – Showcased poster presentations at the American Society of Preventive Cardiology Annual Congress in August 2024 and the 19th Annual Cardiometabolic Health Congress in October 2024 – – Cash, cash equivalents and investments of $314.4 million as of September 30, 2024, providing cash runway into 2027 – NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced its financial results for the third quarter of 2024 and outlined recent business highlights. “We are proud of the continued momentum building at Tourmaline, highlighted by the formation of our Cardiovascular Scientific Advisory Board last month,” said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline.

Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting
seekingalpha.com13 October 2024 Sentiment: POSITIVE

Tourmaline Bio's Pacibekitug shows promise in treating thyroid eye disease, with pivotal phase 2b data expected in 2025 and a phase 3 study starting in 2024. The 7 major thyroid eye disease markets are expected to reach $4.13 billion by 2034. The company is also exploring Pacibekitug for atherosclerotic cardiovascular disease, with phase 2 TRANQUILITY study results anticipated in the first half of 2025.

Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
globenewswire.com11 October 2024 Sentiment: POSITIVE

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that it expects to present two posters at the upcoming 19th Annual Cardiometabolic Health Congress (CMHC), taking place October 17-19, 2024, in Boston, MA. These posters highlight Tourmaline's ongoing commitment to further characterizing inflammatory cardiovascular risk, as well as potential therapeutic mechanisms of IL-6 inhibition.

Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
globenewswire.com08 October 2024 Sentiment: POSITIVE

– Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases – – Cardiovascular Scientific Advisory Board expected to provide strategic guidance as Tourmaline advances pacibekitug towards potential Phase 3 clinical trial readiness in 2025 for the treatment of cardiovascular diseases – NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) --  Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the formation of its Cardiovascular Scientific Advisory Board (CV SAB). The CV SAB is expected to provide strategic guidance and expertise as Tourmaline advances its pacibekitug cardiovascular diseases program, including the TRANQUILITY Phase 2 clinical trial that commenced earlier this year and for which Tourmaline continues to expect topline data in the first half of 2025.

Tourmaline Bio to Present at Upcoming Investor Conferences
globenewswire.com03 September 2024 Sentiment: POSITIVE

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, is expected to participate in the following investor conferences: H.C.

Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
globenewswire.com08 August 2024 Sentiment: POSITIVE

– First patient dosed in May 2024 in Phase 2 TRANQUILITY trial evaluating pacibekitug (TOUR006) in patients with high cardiovascular risk – – On track to initiate a pivotal Phase 3 trial evaluating pacibekitug delivered subcutaneously every 8 weeks as first-line treatment for Thyroid Eye Disease (TED) in the second half of 2024 – – Added to the Russell 2000® Index and the broad-market Russell 3000® Index in June 2024 – – Cash, cash equivalents and investments of $334.4 million as of June 30, 2024, providing cash runway into 2027 – NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced its financial results for the second quarter of 2024 and outlined recent business highlights. “The second quarter of 2024 was another period of strong execution by Tourmaline, including the dosing of the first patient in the Phase 2 TRANQUILITY trial.

Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
globenewswire.com27 June 2024 Sentiment: POSITIVE

NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the promotion of Ryan Robinson, CPA, to Chief Financial Officer and Treasurer, effective June 25, 2024. Mr. Robinson most recently held the role of Vice President, Finance and Controller at Tourmaline, in addition to serving as Tourmaline's Interim Chief Financial Officer and Treasurer since October 2023.

Here's Why Momentum in Tourmaline Bio, Inc. (TRML) Should Keep going
Zacks Investment Research15 March 2024 Sentiment: POSITIVE

Tourmaline Bio, Inc. (TRML) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Tourmaline Bio: TED And ASCVD Targeting With Differentiated IL-6
Seeking Alpha01 November 2023 Sentiment: POSITIVE

Tourmaline Bio is advancing the use of its drug candidate TOUR006 for the treatment of thyroid eye disease and atherosclerotic cardiovascular disease. The ongoing phase 2b spiriTED study, which is using TOUR006 for the treatment of patients with active TED, is expected to release results in the first half of 2025. A phase 2 study, using TOUR006 for the treatment of patients with atherosclerotic cardiovascular disease, is expected to begin in 2024.

What type of business is Tourmaline Bio?

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

What sector is Tourmaline Bio in?

Tourmaline Bio is in the Healthcare sector

What industry is Tourmaline Bio in?

Tourmaline Bio is in the Biotechnology industry

What country is Tourmaline Bio from?

Tourmaline Bio is headquartered in United States

When did Tourmaline Bio go public?

Tourmaline Bio initial public offering (IPO) was on 07 May 2021

What is Tourmaline Bio website?

https://www.tourmalinebio.com

Is Tourmaline Bio in the S&P 500?

No, Tourmaline Bio is not included in the S&P 500 index

Is Tourmaline Bio in the NASDAQ 100?

No, Tourmaline Bio is not included in the NASDAQ 100 index

Is Tourmaline Bio in the Dow Jones?

No, Tourmaline Bio is not included in the Dow Jones index

When was Tourmaline Bio the previous earnings report?

No data

When does Tourmaline Bio earnings report?

The next expected earnings date for Tourmaline Bio is 19 March 2025